Literature DB >> 8808698

The merlin tumor suppressor localizes preferentially in membrane ruffles.

C Gonzalez-Agosti1, L Xu, D Pinney, R Beauchamp, W Hobbs, J Gusella, V Ramesh.   

Abstract

Merlin is a tumor suppressor whose inactivation underlies the familial schwannomas and meningiomas of neurofibromatosis 2 and their sporadic counterparts. It bears striking similarity to the ERM proteins, ezrin, radixin and moesin, members of the protein 4.1 superfamily that link proteins in the cytoskeleton and the plasma membrane. We have generated polyclonal and monoclonal antibodies that detect merlin as an approximately 66 kD protein in many different cell types. Using indirect immunofluorescence we have for the first time visualized endogenous merlin and localized it to the motile regions, such as leading or ruffling edges, in human fibroblast and meningioma cells. Merlin co-localizes with F-actin in these motile regions but is not associated with stress fibers. Merlin does not localize to the same structures as either ezrin or moesin in human meningioma cells, suggesting a function distinct from these ERMs. Thus, merlin is associated with motile regions of the cell and its participation in these structures may be intimately involved in control of proliferation in Schwann cells and meningeal cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808698

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

3.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

4.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

Authors:  A I McClatchey; I Saotome; K Mercer; D Crowley; J F Gusella; R T Bronson; T Jacks
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

5.  Three determinants in ezrin are responsible for cell extension activity.

Authors:  M Martin; C Roy; P Montcourrier; A Sahuquet; P Mangeat
Journal:  Mol Biol Cell       Date:  1997-08       Impact factor: 4.138

6.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.

Authors:  Rong Rong; Xiaoling Tang; David H Gutmann; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-14       Impact factor: 11.205

7.  The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association.

Authors:  M F James; N Manchanda; C Gonzalez-Agosti; J H Hartwig; V Ramesh
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

8.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

9.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

10.  Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

Authors:  Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella
Journal:  Neurobiol Dis       Date:  2007-09-19       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.